Oct 1, 2021

The National Medical Products Administration (NMPA), China’s medical device market regulator, has revealed plans to set up a technical division focused on clinical evaluation of medical devices, as well as issued new guidelines for animal testing studies related to medical devices.

New authority for medical device clinical evaluations

First, the NMPA has announced (link in Chinese) the establishment of a national technical authority to address medical device as well as in vitro diagnostic (IVD) clinical evaluations. The new unit will oversee development and maintenance of general as well as special standards pertaining to clinical evaluations, including the following components:

  • Clinical trial quality management
  • Clinical data management and data exchange
  • Real-world research requirements
  • Clinical data processing

The NMPA announcement also identifies several expert groups that will help steer the new authority; these groups will consist of universities, hospitals and healthcare provider networks, life sciences and medical device company representatives, and regulatory agencies.

Animal testing studies for medical devices

Second, Chinese regulators have published new guidelines (link in Chinese) pertaining to animal testing studies and investigations for medical device registrants.

The NMPA has issued the guidelines in two parts. Part 1 covers decision-making principles to help determine whether animal testing for a device is warranted as well as how to reduce the number of such studies when possible. Part 2 covers test design and quality assurance considerations.

Learn more about Chinese medical device and IVD regulations at Emergo by UL:

  • China NMPA medical device registration and approval consulting
  • Medical device clinical and testing requirements assessment for China
  • Whitepaper: China NMPA medical device registration
  • Webinar: Medical device registration in China

 

 

Author

  • Stewart Eisenhart

Related